Protocols

Novartis plans to open a string of global digital labs; Rgenix snags a $40M round in push toward PhII

Vas Narasimhan has made no secret of his keen interest in making Novartis over with new digital technologies, and now he plans to open new offices around the world to help cement ties with a host of players in the field, from Apple and Google all the way to the upstarts just setting out. Chief digital officer Bertrand Bodson talked to Bloomberg about the digital labs, with the first now open in San Francisco.

Lepu Medical has led a $40 million C round for Rgenix, a biotech company pursuing Phase Ib/II clinical trials of the lead program RGX-104 in “multiple cancer indications.” Novo Holdings A/S, Sofinnova Partners, Alexandria Venture Investments, and the Partnership Fund for New York City’s Innovate NY Fund all joined in.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 34,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->